Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
Status:
Recruiting
Trial end date:
2023-05-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile
following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with
Osteogenesis Imperfecta (OI).